Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa (SOLSTICE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03584165 |
|
Recruitment Status :
Enrolling by invitation
First Posted : July 12, 2018
Last Update Posted : May 8, 2023
|
Sponsor:
NightstaRx Ltd, a Biogen Company
Information provided by (Responsible Party):
Biogen ( NightstaRx Ltd, a Biogen Company )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The objective of the study is to evaluate the long-term safety and efficacy of a sub-retinal injection of BIIB111 in participants with Choroideremia (CHM) who have been previously treated with BIIB111 and who have exited an antecedent study; these treated participants will be compared with untreated control participants who have exited the STAR (NCT03496012) study and BIIB112 in participants with X-linked retinitis pigmentosa (XLRP) who have been previously treated with BIIB112 and who have exited an antecedent study.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Choroideremia X-Linked Retinitis Pigmentosa | Genetic: BIIB111 Genetic: BIIB112 | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 330 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Outcomes Assessor) |
| Primary Purpose: | Other |
| Official Title: | A Long-term Follow-up Study to Evaluate the Safety and Efficacy of Retinal Gene Therapy in Subjects With Choroideremia Previously Treated With Adeno-Associated Viral Vector Encoding Rab Escort Protein-1 (AAV2-REP1) and in Subjects With X-Linked Retinitis Pigmentosa Previously Treated With Adeno-Associated Viral Vector Encoding RPGR (AAV8-RPGR) in an Antecedent Study |
| Actual Study Start Date : | June 4, 2018 |
| Estimated Primary Completion Date : | June 4, 2026 |
| Estimated Study Completion Date : | June 4, 2026 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
|
Experimental: BIIB111
Participants previously treated with sub-retinal injection of BIIB111 in antecedent studies 273CH301 (NCT03496012) and 273CH203 (NCT03507686) will be enrolled. Participants previously treated with this same sub-retinal injection (rAAV2-REP1) in antecedent studies 20150371 (NCT02553135), Pro00028599 (NCT02077361), THOR-TUE-01 (NCT02671539), CHM09/01 (NCT01461213) and REGEN2015 (NCT02407678) will also be invited for enrollment. This is a follow-up study, investigational product was administered in the previous study.
|
Genetic: BIIB111
Administered as specified in the treatment arm.
Other Names:
|
|
Experimental: BIIB112
Participants previously treated with sub-retinal injection of BIIB112 in the antecedent study 274RP101 (NCT03116113) will be enrolled. This is a follow-up study, investigational product was administered in the previous study.
|
Genetic: BIIB112
Administered as specified in the treatment arm.
Other Name: AAV8-RPGR |
|
No Intervention: Untreated
Untreated participants who served as controls in the antecedent study 273CH301 (NCT03496012), investigating treatment with BIIB111, will be enrolled. This is a follow-up study, participants will not be administered study medication nor receive a sham surgery.
|
Primary Outcome Measures :
- Percentage of Participants with Adverse Events (AEs) [ Time Frame: Up to 5 years ]
- Ophthalmic Examination Assessment: Intraocular Pressure (IOP) [ Time Frame: Up to 5 years ]
- Ophthalmic Examination Assessment: Abnormal Slit Lamp Examination [ Time Frame: Up to 5 years ]
- Ophthalmic Examination Assessment: Lens Opacity Grading [ Time Frame: Up to 5 years ]
- Ophthalmic Examination Assessment: Anterior Chamber and Vitreous Inflammation [ Time Frame: Up to 5 years ]
- Ophthalmic Examination Assessment: Indirect Ophthalmoscopy [ Time Frame: Up to 5 years ]
Secondary Outcome Measures :
- Change from Baseline in Best-Corrected Visual Acuity (BCVA) [ Time Frame: Up to 5 years ]BCVA will be assessed for both eyes using the Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart. BCVA test should be performed prior to pupil dilation, and distance refraction should be carried out before BCVA is measured. Initially, letters are read at a distance of 4 meters from the chart. If <20 letters are read at 4 meters, testing at 1 meter should be performed. BCVA is to be reported as number of letters read correctly by the participant using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved.
- Percentage of Participants with no Decrease from Baseline in BCVA or a Decrease from Baseline in BCVA of <5 ETDRS Letters in Choroideremia (CHM) Participants [ Time Frame: Up to 5 years ]BCVA will be assessed for both eyes using the Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart. BCVA test should be performed prior to pupil dilation, and distance refraction should be carried out before BCVA is measured. Initially, letters are read at a distance of 4 meters from the chart. If <20 letters are read at 4 meters, testing at 1 meter should be performed. BCVA is to be reported as number of letters read correctly by the participant using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved.
- Percentage of Participants with an Increase from Baseline in BCVA of ≥10 ETDRS Letters in CHM Participants [ Time Frame: Up to 5 years ]BCVA will be assessed for both eyes using the Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart. BCVA test should be performed prior to pupil dilation, and distance refraction should be carried out before BCVA is measured. Initially, letters are read at a distance of 4 meters from the chart. If <20 letters are read at 4 meters, testing at 1 meter should be performed. BCVA is to be reported as number of letters read correctly by the participant using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved.
- Percentage of Participants with an Increase from Baseline in BCVA of ≥15 ETDRS Letters in CHM Participants [ Time Frame: Up to 5 years ]BCVA will be assessed for both eyes using the Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart. BCVA test should be performed prior to pupil dilation, and distance refraction should be carried out before BCVA is measured. Initially, letters are read at a distance of 4 meters from the chart. If <20 letters are read at 4 meters, testing at 1 meter should be performed. BCVA is to be reported as number of letters read correctly by the participant using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved.
- Assessment of Fundus Autofluorescence (AF) at Each Visit [ Time Frame: Up to 5 years ]Fundus Autofluoroscence will be performed on both eyes to assess the change in the area of viable retinal tissue. It will be reported in square millimetres (mm^2).
- Assessment of Fundus Photography at Each Visit [ Time Frame: Up to 5 years ]Fundus photography will be performed on both eyes following the dilation of the participant's pupils.
- Assessment of Spectral Domain Optical Coherence Tomography (SD-OCT) at Each Visit [ Time Frame: Up to 5 years ]SD-OCT will be performed on both eyes to assess the foveal changes and other potential anatomic changes. The measurements were taken after dilation of the participant's pupil and would be reported in micrometres (µm).
- Assessment of Microperimetry at Each Visit [ Time Frame: Up to 5 years ]Microperimetry will be performed on both eyes to assess changes in retinal sensitivity within the macula. It will be reported in decibels (dB).
- Change from Baseline in 25-Item Visual Function Questionnaire (VFQ-25) [ Time Frame: Up to 5 years ]VFQ-25 questionnaire measures dimensions of self-reported vision-targeted health status that are most important to persons with eye disease. Total score ranges from 0-100, where a score of 0 represents the worst outcome and 100 represents the best outcome.
- Change from Baseline in Visual Field [ Time Frame: Up to 5 years ]The outcome measure will be assessed in BIIB112-treated participants.
- Percentage of Participants with an Increase from Baseline in Luminance Visual Acuity (LLVA) of ≥10 ETDRS Letters in BIIB112-treated Participants [ Time Frame: 18 Months to 60 Months, Post-Day 0 Visits ]The LLVA was measured by placing a 2.0-log-unit neutral density filter over the best correction for that eye and having the participant read the normally illuminated ETDRS chart. The assessment was performed prior to dilating the eyes. Initially, letters are read at a distance of 4 metres from the chart. If <20 letters are read at 4 metres, testing at 1 metre should be performed. BCVA is to be reported as number of letters read correctly by the participant.
- Percentage of Participants with an Increase from Baseline in Luminance Visual Acuity (LLVA) of ≥15 ETDRS Letters in BIIB112-treated Participants [ Time Frame: 18 Months to 60 Months, Post-Day 0 Visits ]The LLVA was measured by placing a 2.0-log-unit neutral density filter over the best correction for that eye and having the participant read the normally illuminated ETDRS chart. The assessment was performed prior to dilating the eyes. Initially, letters are read at a distance of 4 metres from the chart. If <20 letters are read at 4 metres, testing at 1 metre should be performed. BCVA is to be reported as number of letters read correctly by the participant.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Criteria
Key Inclusion Criteria:
CHM Participants
a. Have participated in and exited from an interventional study that investigated the safety and efficacy of a sub-retinal injection of BIIB111 for CHM.
XLRP Participants
a. Have received a sub-retinal injection of BIIB112 for XLRP and have exited an antecedent study.
Key Exclusion Criteria:
Participants are not eligible for study participation if they meet the following exclusion criterion.
a. In the opinion of the Investigator and/or the Sponsor, it is not in the participant's best interest to participate in the study.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03584165
Locations
Show 25 study locations
Sponsors and Collaborators
NightstaRx Ltd, a Biogen Company
Investigators
| Study Director: | Medical Director | Biogen |
| Responsible Party: | NightstaRx Ltd, a Biogen Company |
| ClinicalTrials.gov Identifier: | NCT03584165 |
| Other Study ID Numbers: |
273CH201 2017-003104-42 ( EudraCT Number ) |
| First Posted: | July 12, 2018 Key Record Dates |
| Last Update Posted: | May 8, 2023 |
| Last Verified: | May 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Biogen ( NightstaRx Ltd, a Biogen Company ):
|
NightstaRx Biogen NSR-REP1 CHM Gene Therapy |
AAV REP1 AAV8 RPGR |
Additional relevant MeSH terms:
|
Retinitis Retinitis Pigmentosa Choroideremia Retinal Diseases Eye Diseases Eye Diseases, Hereditary |
Retinal Dystrophies Retinal Degeneration Genetic Diseases, Inborn Choroid Diseases Uveal Diseases Genetic Diseases, X-Linked |